Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alector

- PMLiVE

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

The licence application for the treatment of mild cognitive impairment due to Alzheimer’s disease was made as part of the accelerated approval pathway programme

- PMLiVE

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

There are no approved treatment options available for acute agitation related to dementia

- PMLiVE

FDA grants Prothena fast-track designation for next-generation Alzheimer’s disease therapy

Approximately 50 million people worldwide are estimated to be living with Alzheimer’s disease or other dementias

- PMLiVE

Biogen retracts EMA application for Alzheimer’s drug Aduhelm

The application was pulled after the CHMP said the data provided was not enough to support a marketing authorisation

- PMLiVE

Rare cancer specialists Sierra Oncology acquired by GSK for £1.5bn

Unification will help to uphold and progress promising Momelotinib treatment which targets myelofibrosis

- PMLiVE

GSK and CureVac sign deal with Germany for mRNA COVID-19 vaccines

The agreement is part of a Pandemic Preparedness Contract and means millions of vaccines can be produced at short notice during future public health emergencies

- PMLiVE

Study provides new insights into Alzheimer’s disease

The study used the genomes of 100,000 people with Alzheimer’s and 600,000 healthy individuals

Biogen Idec building

Biogen shares peer-reviewed publication of Aduhelm phase 3 data

The trial data was published in The Journal of Prevention of Alzheimer’s Disease

- PMLiVE

AbbVie acquires Syndesi Therapeutics in $1bn deal

The deal will allow AbbVie to access Syndesi’s research into Alzheimer's disease

Biogen Idec building

Biogen’s Aduhelm unlikely to get approval in Europe

In another setback for the controversial Alzheimer’s disease antibody, the EMA’s review committee has voted against recommending the treatment

- PMLiVE

Eisai/Biogen present more data on antibody for Alzheimer’s disease

Phase 2 data shows lecanemab offers a consistent ‘robust’ effect against Alzheimer’s disease, while the phase 3 programme will test plasma biomarkers to identify preclinical disease

dengue fever mosquito

WHO has recommended GSK’s malaria vaccine for children

This is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links